Key result
Platelet microparticles (PMPs) are actively involved in tumor growth, metastasis, angiogenesis, and the development of multidrug resistance in cancer.
Platelet microparticles play a crucial role in cancer progression and metastasis, highlighting their potential as targets or vectors for anti-cancer therapy.
Answers are grounded in this paper and cite their sources.
PMPs may serve as therapeutic targets in cancer; leaves open the need for clinical validation before practice change.
Extracellular vesicles (EVs) are a heterogeneous group of structures which can be classified into smaller in size and relatively homogenous exosomes (EXSMs)-spherical fragments of lipid bilayers from inner cell compartments-and bigger in size ectosomes (ECSMs)-a direct consequence of cell-membrane blebbing. EVs can be found in body fluids of healthy individuals. Their number increases in cancer and other pathological conditions. EVs can originate from various cell types, including leukocytes, erythrocytes, thrombocytes, and neoplastic cells. Platelet microparticles (PMPs) are the most abundant population of EVs in blood. It is well documented that PMPs, being a crucial element of EVs signaling, are involved in tumor growth, metastasis, and angiogenesis and may participate in the development of multidrug resistance by tumor cells. The aim of this review is to present the role of PMPs in carcinogenesis. The biology and functions of PMPs with a particular emphasis on the most recent scientific reports on EV properties are also characterized.
No takes yet. Share an insight, caveat, or question.
Żmigrodzka et al. (2016) conducted a review in Cancer. Platelet microparticles (PMPs) was evaluated. Platelet microparticles (PMPs) are actively involved in tumor growth, metastasis, angiogenesis, and the development of multidrug resistance in cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: